FLAG-liposomal doxorubicin (myocet) regimen for refractory or relapsed acute leukemia pediatric patients

Journal of Pediatric Hematology/Oncology

Volumn 34, Issue 3, 2012, Pages 208-216

  Quarello, Paola ^a   Berger, Massimo ^a   Rivetti, Elisa ^a   Galletto, Chiara ^a   Masetti, Riccardo ^b   Manicone, Rosaria ^a   Barisone, Elena ^a   Pession, Andrea ^b   Fagioli, Franca ^a  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

acute leukemia; HSCT; relapse

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; COTRIMOXAZOLE; CYTARABINE; DOXORUBICIN; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PREDNISOLONE; STEROID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN TISSUE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MULTIPLE CYCLE TREATMENT; MYCOSIS; OVERALL SURVIVAL; PNEUMOCYSTOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYTARABINE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM RECURRENCE, LOCAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; VIDARABINE;

EID: 84859210868     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182427593     Document Type: Article

References (26)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178.
2. Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia. 2005;19:2025-2029. (Pubitemid 41741594)
3. Rubnitz JE. Childhood acute myeloid leukemia. Curr Treat Options Oncol. 2008;9:95-105.
4. Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica. 2007;92:1519-1532. (Pubitemid 350144128)
5. Moricke A, ZimmermannM, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24:265-284.
6. Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol. 1994;12:671-678.
7. Keating MJ, O'Brien S, Robertson LE, et al. The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma. 1994;14(suppl 2):11-16. (Pubitemid 24322862)
8. Gandhi V, Plunkett W, Weller S, et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol. 2001;19:2142-2152. (Pubitemid 32366968)
9. Estey E, Plunkett W, Gandhi V, et al. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 1993;9:343-350. (Pubitemid 23209513)
10. Visani G, Tosi P, Zinzani PL, et al. FLAG (fludarabine +high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of "poor risk" acute myeloid leukemias. Leukemia. 1994;8:1842-1846. (Pubitemid 24363058)
11. Montillo M, Tedeschi A, Centurioni R, et al. Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colonystimulating factor (FLAG-GCSF). Leuk Lymphoma. 1997;25: 579-583. (Pubitemid 27361905)
12. Montillo M, Mirto S, Petti MC, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol. 1998;58:105-109. (Pubitemid 28268085)
13. Fleischhack G, Hasan C, Graf N, et al. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol. 1998;102:647-655. (Pubitemid 28387045)
14. Russo D, Piccaluga PP, Michieli M, et al. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia. Ann Hematol. 2002;81:462-466. (Pubitemid 36067660)
15. Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in longcirculating liposomes. Cancer Res. 1992;52:891-896.
16. Camera A, Rinaldi CR, Palmieri S, et al. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients. Ann Hematol. 2009;88:151-158.
17. Clavio M, Venturino C, Pierri I, et al. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Ann Hematol. 2004;83:696-703. (Pubitemid 39440214)
18. Kaspers GJL, Zimmermann M, Reinhardt D, et al. Addition of liposomal daunorubicin (DaunoXome) to FLAG significantly improves treatment response in pediatric relapsed AML: final results from the international randomised phase III study relapsed AML 2001/01. Blood. 2009;114:18.
19. Melillo LRG, Rossi G, Dell'Olio M, et al. Combination of non-pegylated liposomal Doxorubicin (Myocet®) with FLAG regimen in patients with acute myeloid leukemia. Haematologica. 2008;93(suppl 1):480; abstract 1239.
20. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19:1444-1454. (Pubitemid 32202552)
21. Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002;94:25-36. (Pubitemid 34049039)
22. McCarthy AJ, Pitcher LA, Hann IM, et al. FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children. Med Pediatr Oncol. 1999;32:411-415. (Pubitemid 29249740)
23. Leahey A, Kelly K, Rorke LB, et al. A phase I/II study of idarubicin (Ida) with continuous infusion fludarabine (F-ara- A) and cytarabine (ara-C) for refractory or recurrent pediatric acute myeloid leukemia (AML). J Pediatr Hematol Oncol. 1997;19:304-308. (Pubitemid 27464887)
24. Dinndorf PA, Avramis VI, Wiersma S, et al. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. J Clin Oncol. 1997;15: 2780-2785. (Pubitemid 27330003)
25. Huhmann IM, Watzke HH, Geissler K, et al. FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol. 1996;73: 265-271. (Pubitemid 27032720)
26. Allen TM. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs. 1998;56:747-756.